Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 21

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 21
---
 | ) |     |           | (396,674 | ) |     |                       | (397,375 | ) |
| Total equity                                                                                                                 |     |                          |    8,505 |   |     |           |   16,254 |   |     |                       |   16,055 |   |
| Total non- current liabilities and equity                                                                                    |     | $                        |   27,780 |   |     | $         |   35,529 |   |     | $                     |   35,330 |   |

S - 10 The above table is based on 1,199,859,190 ordinary shares, represented by 79,990,613 ADSs outstanding as of September 30, 2024 and excludes as of such date:

| • | 61,822,395 ordinary shares, represented by 4,121,493 ADSs issued in the November 2024 Registered Direct Offering; |

| • | 85,145,940 ordinary shares, represented by 5,676,396 ADSs issued in January 2025 through its “at-the-market” equity offering program with H.C. Wainwright & Co., LLC, as sales agent; |

| • | 300,829,719 ordinary shares, represented by 20,055,315 ADSs, issuable upon the exercise of outstanding warrants, at a weighted average exercise price of $0.08 per share (or $1.13 per ADS); |

| • | 118,411,755 ordinary shares, represented by 7,894,117 ADSs, issuable upon the exercise of outstanding options under our Amended and Restated 2003 Share Incentive Plan, or the Share Incentive Plan, at a weighted average exercise price of 
 $0.11 per share (or $1.71 per ADS);                                                                                                                                                                                                          |

| • | 32,431,095 ordinary shares, represented by 2,162,073 ADSs, issuable upon the vesting of restricted stock units and performance stock units under our Share Incentive Plan, with exercise prices ranging from $0 to $0.03 with respect to 
 ordinary shares and $0 to $0.42 with respect to ADSs;                                                                                                                                                                                    |

| • | 49,269,450 ordinary shares, represented by 3,284,630 ADSs, reserved for future issuance under the Share Incentive Plan; |

| • | 185